CD93 and migraine disorder: In a study on migraines [59, 60], it was found that patients with a genetic defect in the complement 1 inhibitor manifested migraine-like episodes, and using a C1 esterase inhibitor (C1-INH) could block the C1q-C1qR pathway to improve migraine disability.